Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Cisplatin-gemcitabine is highly active in BRCA/PALB2+ pancreatic cancer

Key clinical point: Veliparib does not significantly improve on the high efficacy of combination cisplatin and gemcitabine as first-line therapy for germline BRCA- or PALB2-mutated PDAC.

Major finding: The response rate was 65.2% with cisplatin-gemcitabine alone and 74.1% with cisplatin-gemcitabine plus veliparib (P = .55).

Study details: A phase 2 randomized controlled trial among 52 patients with untreated locally advanced or metastatic PDAC having a germline BRCA or PALB2 mutation.

Disclosures: Dr. O’Reilly disclosed that she has relationships with numerous pharmaceutical companies. The trial was funded by the Lustgarten Foundation, the David M. Rubenstein Center for Pancreatic Cancer Research, the Reiss Family Foundation, the National Cancer Institute’s Cancer Therapy Evaluation Program, and NCI grants. Dr. Schilsky disclosed that he has no conflicts of interest.


O’Reilly EM et al. 2020 GI Cancers Symposium. Abstract 639.